Lin BioScience, Inc. Statistics
Lin BioScience, Inc. (6696) Stock Statistics & Valuation Metrics
Total Valuation
Lin BioScience, Inc. has a market cap or net worth of TWD 123.59B. The enterprise value is ―.
- Market Cap
- TWD 123.59B
- Enterprise Value
- ―
Share Statistics
Lin BioScience, Inc. has 835,060,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 835,060,000
- Owned by Insiders
- ―
- Owned by Institutions
- 0.12%
Financial Efficiency
Lin BioScience, Inc.’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -11.12%.
- Return on Equity (ROE)
- -0.13
- Return on Assets (ROA)
- -0.05
- Return on Invested Capital (ROIC)
- -11.12%
- Return on Capital Employed (ROCE)
- -0.11
- Revenue Per Employee
- 0
- Profits Per Employee
- -68.14M
- Employee Count
- 20
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Lin BioScience, Inc. is -11.95. Lin BioScience, Inc.’s PEG ratio is 0.14.
- PE Ratio
- -11.95
- PS Ratio
- 0.00
- PB Ratio
- 13.03
- Price to FCF
- -73.67
- Price to Operating Cash Flow
- -74.68
- PEG Ratio
- 0.14
Income Statement
In the last 12 months, Lin BioScience, Inc. had revenue of 0 and earned -1.36B in profits. Earnings per share was -16.73.
- Revenue
- 0
- Gross Profit
- -23.79M
- Operating Income
- -2.86B
- Pretax Income
- -2.64B
- Net Income
- -1.36B
- EBITDA
- -2.61B
- Earnings Per Share (EPS)
- -16.73
Cash Flow
In the last 12 months, operating cash flow was -1.85B and capital expenditures -26.09M, giving a free cash flow of -1.87B billion.
- Operating Cash Flow
- -1.85B
- Free Cash Flow
- -1.87B
- Free Cash Flow per Share
- -2.26
Dividends & Yields
Lin BioScience, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.43%
- Earnings Yield
- -1.46%
Stock Price Statistics
- Beta
- 0.62
- 52-Week Price Change
- 408.59%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 40.96
- Average Volume (3m)
- 11.87M
Financial Position
Lin BioScience, Inc. as a current ratio of 58.18, with Debt / Equity ratio of 0.21%
- Current Ratio
- 58.18
- Quick Ratio
- 58.18
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 4.55
- Interest Coverage Ratio
- -2812.04
Taxes
In the past 12 months, Lin BioScience, Inc. has paid -55.33M in taxes.
- Income Tax
- -55.33M
- Effective Tax Rate
- 0.02
Enterprise Valuation
Lin BioScience, Inc. EV to EBITDA ratio is -28.36, with an EV/FCF ratio of -65.04.
- EV to Sales
- 0.00
- EV to EBITDA
- -28.36
- EV to Free Cash Flow
- -65.04
- EV to Operating Cash Flow
- -65.95
Balance Sheet
Lin BioScience, Inc. has TWD 16.60B in cash and marketable securities with TWD 92.72M in debt, giving a net cash position of TWD 16.50B billion.
- Cash & Marketable Securities
- TWD 16.60B
- Total Debt
- TWD 92.72M
- Net Cash
- TWD 16.50B
- Net Cash Per Share
- TWD 19.76
- Tangible Book Value Per Share
- TWD 30.70
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Lin BioScience, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -52.82%
